In early-phase development, benefit–risk (B/R) assessment is often treated as a downstream regulatory exercise. It should be one of the first strategic disciplines applied to a programme: the mechanism by which limited, uncertain and fast-moving evidence is translated into decisions that protect participants while preserving scientific momentum.
International Clinical Trials has recently featured Linical in an article by Pilar Larrodera. The article examines the critical role of benefit–risk (B/R) assessment and proactive pharmacovigilance (PV) in early-phase clinical development. It argues that B/R assessment should not be viewed as a late-stage regulatory requirement, but as a foundational strategy that guides early decision-making when evidence is limited and uncertainty is high. The article also highlights how pharmacovigilance must evolve from a compliance function to a strategic decision partner, ensuring uncertainties are made explicit and actively managed throughout the trial.
This article is taken from International Clinical Trials, November 2026, pages 68-71 . © Samedan Ltd